Use of putative hepatoprotective agents as an adjunct to anti-TB treatment in Europe

20251 citationsJournal Articlediamond Open Access

Authors

Ohanna Kirakosyan · Research Center Borstel - Leibniz Lung Center

Maja Reimann · Research Center Borstel - Leibniz Lung Center

Åse Bengård Andersen · Odense University Hospital

Agnar Bjarnason · University of Iceland

Ágnes Bakos · Országos Korányi Tbc és Pulmonológiai Intézet

Anne Ma Dyrhol‐Riise · Oslo University Hospital

Anne-Marie McLaughlin

Abstract

Putative hepatoprotective agents are widely used as an adjunct to TB treatment in the WHO European Region, particularly in the countries of the former Soviet Union, some of which have included them in their national guidelines.

Topics & Keywords

Drug-Induced Hepatotoxicity and Protection Pharmacological Effects of Natural Compounds Tuberculosis Research and Epidemiology

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: IJTLD OPEN

Volume 2, Issue 2, pp. 101-106

DOI: 10.5588/ijtldopen.24.0498

Field-Weighted Citation Impact: 1.53